Subscription Support
Contact MMHInfo@mmhgroup.com for subscription-related questions only.
Press Releases and News Announcements
Send press releases and other announcements relevant to the pharma c-suite to pharmexec@mjhlifesciences.com.
Submit Article and/or Podcast Proposals
Use this form to submit article/podcast proposals.
Mike Hollan
Assistant Managing Editor
mhollan@mjhlifesciences.com
Michael Christel
Group Managing Editor
mchristel@mjhlifesciences.com
Miranda Schmalfuhs
Group Social Media Editor
mschmalfuhs@mjhlifesciences.com
Don Tracy
Associate Editor
dtracey@mjhlifesciences.com
Colleen Hall
Vice President, Content and Special Projects
Jeanne Linke
Managing Editor
Megan Manzano
Senior Editor
Shannon Stolz
Senior Editor
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Grants Priority Review to Regeneron’s Eylea for Macular Edema Following Retinal Vein Occlusion
April 18th 2025Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks achieved non-inferior visual acuity outcomes compared to Eylea in patients with macular edema following retinal vein occlusion.